Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95079 trials found · Page 152 of 4754
-
New injection plus chemo aims to wipe out stomach cancer before surgery
Disease control Not yet recruitingThe research study is being conducted to study whether performing injections of a new treatment, called RP2, directly into stomach and esophagus tumors along with standard chemotherapy (called FLOT) is safe and whether it does a better job of killing cancer before surgery compare…
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
One shot showdown: can a new HPV vaccine match the gold standard?
⭐️ VACCINE ⭐️ Not yet recruitingThe goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months post vaccination. The vaccine will be given randomly…
Phase: PHASE4 • Sponsor: International Agency for Research on Cancer • Aim: ⭐️ VACCINE ⭐️
Last updated May 13, 2026 16:01 UTC
-
New hope for early lung cancer: drug duo plus radiation tested
Disease control Not yet recruitingMajor objectives to evaluate the efficacy and safety of lparomlimab and Tuvonralimab Injection ((QL1706, an Anti-PD-1/CTLA-4 Combined Antibody)) combined with SBRT in patients with early-stage non-small cell lung cancer.
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 16, 2026 09:02 UTC
-
Ovarian cancer trial uses KELIM score to decide best time for surgery
Disease control Not yet recruitingA prospective, international, multi-center, interventional trial of advanced epithelial ovarian cancer patients offered three cycles of neoadjuvant chemotherapy (NACT) and triaged with KELIM score. Patients with favorable score will undergo interval debulking surgery (IDS) follow…
Phase: NA • Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for hard-to-treat breast cancer: SYS6010 enters phase 3 trial
Disease control Not yet recruitingThis study is a multicenter, randomized, open-label, parallel-control Phase III clinical trial enrolling patients with unresectable HER2-negative, EGFR-positive recurrent/metastatic breast cancer who have previously failed first- or second-line chemotherapy. It aims to compare th…
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New combo therapy targets lung cancer brain tumors in early trial
Disease control Not yet recruitingPatients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with brain metastases remain a major clinical challenge. Although EGFR-TKIs have demonstrated intracranial activity, disease control is still suboptimal in some patients. Limertinib (…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Engineered immune cells take on tough leukemia in kids
Disease control Not yet recruitingThis study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML. Subjects will be enrolled into one of two treatment cohorts: subjects who will re…
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Promising drug may tame rare blood vessel disease and cut steroid use
Disease control Not yet recruitingTakayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion. Patients with TAK have a high morbidity rate, 50% will relapse and experience a vascular compli…
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for hard-to-treat leukemia: experimental drug enters final testing phase
Disease control Not yet recruitingA Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs
Phase: PHASE3 • Sponsor: Shenzhen TargetRx Co., Ltd. • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThe goal of this clinical trial is to learn whether a high- and low-dose radiotherapy regimen followed by anti-angiogenic TKI and anti-PD-1 antibody therapy works to treat advanced metastatic colorectal cancer. It will also evaluate long-term survival outcomes and explore potenti…
Phase: PHASE2 • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New lung cancer drug shows promise in Early-Stage trial
Disease control Not yet recruitingThis study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well it works when given alone or with chemotherapy. The study is for adults with early stage or locally advanced non-small cell lung cancer (NSCLC) that may or …
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated May 16, 2026 08:49 UTC
-
New drug aims to tackle high blood pressure and obesity together
Disease control Not yet recruitingA multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for lymphoma patients: drug may keep cancer in check
Disease control Not yet recruitingThis is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL) who achieve complete response after induction thera…
Phase: PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 16, 2026 08:49 UTC
-
New program aims to stop child exploitation before it starts
Prevention Not yet recruitingAlthough the exact scope of commercial sexual exploitation of children (CSEC) remains unknown, its significant negative physical and emotional consequences for children has been well-documented. The U.S. government recognized the need for improved CSEC prevention over two decades…
Phase: NA • Sponsor: University of New Hampshire • Aim: Prevention
Last updated May 16, 2026 08:51 UTC
-
Robot bronchoscope aims to diagnose and treat lung cancer in one go
Disease control Not yet recruitingUsing RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ab…
Phase: NA • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Ready-Made immune cells take on lymphoma and leukemia in first human trial
Disease control Not yet recruitingPhase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101
Phase: PHASE1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated May 04, 2026 16:29 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug trial launches
Disease control Not yet recruitingThis is a Phase II Study of HLX43 in Hormone Receptor Positive,HER-2 negative Locally Advanced or Metastatic Breast Cancer Patients with Disease Progression on Standard of Care. Eligible subjects will be treated with the study drug until the loss of clinical benefit, death, intol…
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New combo aims to stop AML from coming back
Disease control ENROLLING_BY_INVITATIONThis study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment of patients with AML after remission, providing hig…
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated May 16, 2026 08:50 UTC
-
Can a herbal capsule slash liver cancer risk in hepatitis b patients?
Disease control Not yet recruitingThis study aims to establish a prospective, multicenter, randomized, double-blind, placebo-controlled parallel-group clinical trial cohort. The cohort will include high-risk populations for hepatitis B cirrhosis-related hepatocellular carcinoma (HCC) from multiple centers nationw…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 16, 2026 08:52 UTC
-
New drug aims to halt small cell lung cancer after chemo-radiation
Disease control Not yet recruitingThis study aims to evaluate the efficacy and safety of adebrelimab consolidation therapy after progression-free response of concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer. This study plans to enroll patients with untreated limited-stage small c…
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 14, 2026 12:01 UTC